Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5631131 | 1.00 | KMT2A (0.47) | KMT2AMDM2MDM4TP53IDO1 | |
| SCHEMBL30385583 | 0.96 | MDM2 (0.48) | KMT2AMDM2MDM4TP53 | |
| SCHEMBL30403561 | 0.96 | MDM2 (0.48) | KMT2AMDM2MDM4TP53 | |
| SCHEMBL28982175 | 0.96 | MDM2 (0.48) | KMT2AMDM2MDM4TP53 | |
| SCHEMBL28982176 | 0.96 | MDM2 (0.48) | KMT2AMDM2MDM4TP53 | |
| SCHEMBL1000225 | 0.91 | MDM2 (0.52) | KMT2AMDM2MDM4TP53IDO1 | |
| SCHEMBL29398859 | 0.91 | MDM2 (0.52) | KMT2AMDM2MDM4TP53IDO1 | |
| SCHEMBL3348411 | 0.91 | MDM2 (0.52) | KMT2AMDM2MDM4TP53IDO1 | |
| SCHEMBL999883 | 0.91 | MDM2 (0.52) | KMT2AMDM2MDM4TP53IDO1 | |
| SCHEMBL29402190 | 0.91 | MDM2 (0.52) | KMT2AMDM2MDM4TP53IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491741-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491741-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20070185128-A1 | Compounds and compositions for treating obesity | NOVO NORDISK A/S (DK) | 2007-08-09 | — | — | US | disclosed |
| US-20070155671-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER | 2007-07-05 | — | — | US | disclosed |
| US-20070155671-A1 | Diaminopropionic acid derivatives | FOTOUHI NADER | 2007-07-05 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217728-B2 | Diaminopropionic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-05-15 | — | — | US | disclosed |
| EP-1572669-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004048345-A2 | 2,5-DIKETOPIPERAZINES FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185128-A1 | Compounds and compositions for treating obesity | MC4R, MC5R, MC3R | KMT2A 2554/4885MDM2 4773/4885MDM4 4869/4885 |
| US-20070155671-A1 | Diaminopropionic acid derivatives | AIFM1, HIF1A, AIFM2 | KMT2A 4000/4885MDM2 3095/4885MDM4 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.